Rachel M Squillace


Affiliation: ARIAD Pharmaceuticals
Country: USA


  1. Squillace R, Miller D, Wardwell S, Wang F, Clackson T, Rivera V. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012;41:425-32 pubmed publisher
  2. Squillace R, Miller D, Cookson M, Wardwell S, Moran L, Clapham D, et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther. 2011;10:1959-68 pubmed publisher
    ..These results underscore the promise of ridaforolimus as a single agent or combination treatment of these tumor types and suggest novel potential predictive biomarkers of sensitivity to an mTOR inhibitor based on cell-cycle status...